Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges

Clinical Microbiology Reviews

Volumn 30, Issue 1, 2017, Pages 409-447

  Wong, Darren ^a   Nielsen, Travis B ^a   Bonomo, Robert A ^b   Pantapalangkoor, Paul ^a   Luna, Brian ^a   Spellberg, Brad ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c LAC USC MEDICAL CENTER   (United States)

Author keywords

Acinetobacter; Acinetobacter baumannii; Acinetobacter calcoaceticus

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEMASE; CIPROFLOXACIN; COLISTIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ETHAMBUTOL; ISONIAZID; LIPOPOLYSACCHARIDE; OUTER MEMBRANE PROTEIN; PHOSPHOLIPASE D; PYRAZINAMIDE; RIFAMPICIN; SIDEROPHORE; TOLL LIKE RECEPTOR 4; VIRULENCE FACTOR;

ACINETOBACTER INFECTION; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPIRATION PNEUMONIA; BACTEREMIA; BACTERIAL CLEARANCE; CLINICAL OUTCOME; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; HISTOPATHOLOGY; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; IMMUNOCOMPROMISED PATIENT; MINIMUM INHIBITORY CONCENTRATION; MORTALITY RATE; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHENOTYPE; PHOTOTHERAPY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEPSIS; SURVIVAL RATE; URINARY TRACT INFECTION; ACINETOBACTER; ACINETOBACTER INFECTIONS; CLINICAL TRIAL (TOPIC); COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; TIME TO TREATMENT;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; TIME-TO-TREATMENT; VIRULENCE FACTORS;

EID: 85007173821     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00058-16     Document Type: Article

References (348)

1. Glew RH, Moellering RC, Jr, Kunz LJ. 1977. Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) 56: 79-97. https://doi.org/10.1097/00005792-197703000-00001.
2. Daly AK, Postic B, Kass EH. 1962. Infections due to organisms of the genus Herellea. B5W and B anitratum. Arch Intern Med 110: 580-591. https://doi.org/10.1001/archinte.1962.03620230026006.
3. Al Atrouni A, Joly-Guillou ML, Hamze M, Kempf M. 2016. Reservoirs of non-baumannii Acinetobacter species. Front Microbiol 7: 49. https:// doi.org/10.3389/fmicb.2016.00049.
4. Dijkshoorn L, van der Toorn J. 1992. Acinetobacter species: which do we mean? Clin Infect Dis 15: 748-749. https://doi.org/10.1093/clind/15.4.748.
5. Chang WN, Lu CH, Huang CR, Chuang YC. 2000. Community-acquired Acinetobacter meningitis in adults. Infection 28: 395-397. https:// doi.org/10.1007/s150100070013.
6. Visca P, Seifert H, Towner KJ. 2011. Acinetobacter infection-an emerging threat to human health. IUBMB Life 63: 1048-1054. https://doi.org/10.1002/iub.534.
7. Dortet L, Legrand P, Soussy CJ, Cattoir V. 2006. Bacterial identification, clinical significance, and antimicrobial susceptibilities of Acinetobacter ursingii and Acinetobacter schindleri, two frequently misidentified opportunistic pathogens. J Clin Microbiol 44: 4471-4478. https://doi.org/10.1128/JCM.01535-06.
8. Loubinoux J, Mihaila-Amrouche L, Le Fleche A, Pigne E, Huchon G, Grimont PA, Bouvet A. 2003. Bacteremia caused by Acinetobacter ursingii. J Clin Microbiol 41: 1337-1338. https://doi.org/10.1128/JCM.41.3.1337-1338.2003.
9. Endo S, Sasano M, Yano H, Inomata S, Ishibashi N, Aoyagi T, Hatta M, Gu Y, Yamada M, Tokuda K, Kitagawa M, Kunishima H, Hirakata Y, Kaku M. 2012. IMP-1-producing carbapenem-resistant Acinetobacter ursingii from Japan. J Antimicrob Chemother 67: 2533-2534. https://doi.org/10.1093/jac/dks249.
10. Chiu CH, Lee YT, Wang YC, Yin T, Kuo SC, Yang YS, Chen TL, Lin JC, Wang FD, Fung CP. 2015. A retrospective study of the incidence, clinical characteristics, identification, and antimicrobial susceptibility of bacteremic isolates of Acinetobacter ursingii. BMC Infect Dis 15: 400. https:// doi.org/10.1186/s12879-015-1145-z.
11. Salzer HJ, Rolling T, Schmiedel S, Klupp EM, Lange C, Seifert H. 2016. Severe community-acquired bloodstream infection with Acinetobacter ursingii in person who injects drugs. Emerg Infect Dis 22: 134-137. https://doi.org/10.3201/eid2201.151298.
12. Nemec A, Krizova L, Maixnerova M, Sedo O, Brisse S, Higgins PG. 2015. Acinetobacter seifertii sp. nov., a member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated from human clinical specimens. Int J Syst Evol Microbiol 65: 934-942. https://doi.org/10.1099/ijs.0.000043.
13. Kishii K, Kikuchi K, Tomida J, Kawamura Y, Yoshida A, Okuzumi K, Moriya K. 2016. The first cases of human bacteremia caused by Acinetobacter seifertii in Japan. J Infect Chemother 22: 342-345. https:// doi.org/10.1016/j.jiac.2015.12.002.
14. Yang Y, Wang J, Fu Y, Ruan Z, Yu Y. 2016. Acinetobacter seifertii isolated from China: genomic sequence and molecular epidemiology analyses. Medicine (Baltimore) 95: e2937. https://doi.org/10.1097/ MD.0000000000002937.
15. Chusri S, Chongsuvivatwong V, Rivera JI, Silpapojakul K, Singkhamanan K, McNeil E, Doi Y. 2014. Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii. Antimicrob Agents Chemother 58: 4172-4179. https://doi.org/10.1128/ AAC.02992-14.
16. Rafei R, Hamze M, Pailhories H, Eveillard M, Marsollier L, Joly-Guillou ML, Dabboussi F, Kempf M. 2015. Extrahuman epidemiology of Acinetobacter baumannii in Lebanon. Appl Environ Microbiol 81: 2359-2367. https://doi.org/10.1128/AEM.03824-14.
17. Zhang WJ, Lu Z, Schwarz S, Zhang RM, Wang XM, Si W, Yu S, Chen L, Liu S. 2013. Complete sequence of the bla(NDM-1)-carrying plasmid pNDM-AB from Acinetobacter baumannii of food animal origin. J Antimicrob Chemother 68: 1681-1682. https://doi.org/10.1093/jac/dkt066.
18. Lupo A, Vogt D, Seiffert SN, Endimiani A, Perreten V. 2014. Antibiotic resistance and phylogenetic characterization of Acinetobacter baumannii strains isolated from commercial raw meat in Switzerland. J Food Prot 77: 1976-1981. https://doi.org/10.4315/0362-028X.JFP-14-073.
19. Berlau J, Aucken HM, Houang E, Pitt TL. 1999. Isolation of Acinetobacter spp. including A. baumannii from vegetables: implications for hospitalacquired infections. J Hosp Infect 42: 201-204. https://doi.org/10.1053/ jhin.1999.0602.
20. Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. 1997. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J Clin Microbiol 35: 2819-2825.
21. Patil JR, Chopade BA. 2001. Distribution and in vitro antimicrobial susceptibility of Acinetobacter species on the skin of healthy humans. Natl Med J India 14: 204-208.
22. Berlau J, Aucken H, Malnick H, Pitt T. 1999. Distribution of Acinetobacter species on skin of healthy humans. Eur J Clin Microbiol Infect Dis 18: 179-183. https://doi.org/10.1007/s100960050254.
23. Griffith ME, Ceremuga JM, Ellis MW, Guymon CH, Hospenthal DR, Murray CK. 2006. Acinetobacter skin colonization of US Army soldiers. Infect Control Hosp Epidemiol 27: 659-661. https://doi.org/10.1086/506596.
24. Spellberg B, Bonomo RA. 2014. The deadly impact of extreme drug resistance in Acinetobacter baumannii. Crit Care Med 42: 1289-1291. https://doi.org/10.1097/CCM.0000000000000181.
25. Maragakis LL, Perl TM. 2008. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46: 1254-1263. https://doi.org/10.1086/529198.
26. Joly-Guillou ML. 2005. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 11: 868-873. https://doi.org/10.1111/j.1469-0691.2005.01227.x.
27. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. 2013. Antimicrobialresistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 34: 1-14. https://doi.org/10.1086/668770.
28. Rodriguez-Bano J, Cisneros JM, Fernandez-Cuenca F, Ribera A, Vila J, Pascual A, Martinez-Martinez L, Bou G, Pachon J, Grupo de Estudio de Infeccion Hospitalaria (GEIH). 2004. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 25: 819-824. https://doi.org/10.1086/502302.
29. Agodi A, Auxilia F, Barchitta M, Brusaferro S, D’Alessandro D, Montagna MT, Orsi GB, Pasquarella C, Torregrossa V, Suetens C, Mura I, GISIO. 2010. Building a benchmark through active surveillance of intensive care unit-acquired infections: the Italian network SPIN-UTI. J Hosp Infect 74: 258-265. https://doi.org/10.1016/j.jhin.2009.08.015.
30. Martins AF, Kuchenbecker RS, Pilger KO, Pagano M, Barth AL, CMCIES-PMPA/SMS Task Force. 2012. High endemic levels of multidrug-resistant Acinetobacter baumannii among hospitals in southern Brazil. Am J Infect Control 40: 108-112. https://doi.org/10.1016/j.ajic.2011.03.010.
31. Labarca JA, Salles MJ, Seas C, Guzman-Blanco M. 2016. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America. Crit Rev Microbiol 42: 276-292. https://doi.org/10.3109/1040841X.2014.940494.
32. Villar M, Cano ME, Gato E, Garnacho-Montero J, Miguel Cisneros J, Ruiz de Alegria C, Fernandez-Cuenca F, Martinez-Martinez L, Vila J, Pascual A, Tomas M, Bou G, Rodriguez-Bano J, GEIH/GEMARA/REIPI-Ab20101 Group. 2014. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine (Baltimore) 93: 202-210. https://doi.org/10.1097/MD.0000000000000036.
33. Gupta V, Datta P, Chander J. 2006. Prevalence of metallo-beta lactamase (MBL) producing Pseudomonas spp. and Acinetobacter spp. in a tertiary care hospital in India. J Infect 52: 311-314. https://doi.org/10.1016/j.jinf.2005.08.013.
34. Mathai AS, Oberoi A, Madhavan S, Kaur P. 2012. Acinetobacter infections in a tertiary level intensive care unit in northern India: epidemiology, clinical profiles and outcomes. J Infect Public Health 5: 145-152. https://doi.org/10.1016/j.jiph.2011.12.002.
35. Bali NK, Fomda BA, Bashir H, Zahoor D, Lone S, Koul PA. 2013. Emergence of carbapenem-resistant Acinetobacter in a temperate north Indian State. Br J Biomed Sci 70: 156-160. https://doi.org/10.1080/09674845.2013.11669950.
36. Shah S, Singhal T, Naik R. 2015. A 4-year prospective study to determine the incidence and microbial etiology of surgical site infections at a private tertiary care hospital in Mumbai, India. Am J Infect Control 43: 59-62. https://doi.org/10.1016/j.ajic.2014.10.002.
37. Golia S, Sangeetha KT, Vasudha CL. 2013. Microbial profile of early and late onset ventilator associated pneumonia in the intensive care unit of a tertiary care hospital in Bangalore, India. J Clin Diagn Res 7: 2462-2466. https://doi.org/10.7860/JCDR/2013/6344.3580.
38. Ginawi I, Saleem M, Sigh M, Vaish AK, Ahmad I, Srivastava VK, Abdullah AF. 2014. Hospital acquired infections among patients admitted in the medical and surgical wards of a non-teaching secondary care hospital in northern India. J Clin Diagn Res 8: 81-83. https://doi.org/10.7860/ JCDR/2014/6673.4014.
39. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, So TM, Yasin RM, Hsueh PR, Carlos CC, Hsu LY, Buntaran L, Lalitha MK, Kim MJ, Choi JY, Kim SI, Ko KS, Kang CI, Peck KR. 2011. High prevalence of multidrug-resistant nonfermenters in hospitalacquired pneumonia in Asia. Am J Respir Crit Care Med 184: 1409-1417. https://doi.org/10.1164/rccm.201102-0349OC.
40. Kuo SC, Chang SC, Wang HY, Lai JF, Chen PC, Shiau YR, Huang IW, Lauderdale TL, TSAR Hospitals. 2012. Emergence of extensively drugresistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infect Dis 12: 200. https://doi.org/10.1186/1471-2334-12-200.
41. Dejsirilert S, Tiengrim S, Sawanpanyalert P, Aswapokee N, Malathum K. 2009. Antimicrobial resistance of Acinetobacter baumannii: six years of National Antimicrobial Resistance Surveillance Thailand (NARST) surveillance. J Med Assoc Thai 92(Suppl 4): S34-S45.
42. Madani N, Rosenthal VD, Dendane T, Abidi K, Zeggwagh AA, Abouqal R. 2009. Health-care associated infections rates, length of stay, and bacterial resistance in an intensive care unit of Morocco: findings of the International Nosocomial Infection Control Consortium (INICC). Int Arch Med 2: 29. https://doi.org/10.1186/1755-7682-2-29.
43. Luna CM, Rodriguez-Noriega E, Bavestrello L, Guzman-Blanco M. 2014. Gram-negative infections in adult intensive care units of Latin America and the Caribbean. Crit Care Res Pract 2014: 480463. https://doi.org/10.1155/2014/480463.
44. Spellberg B, Rex JH. 2013. The value of single-pathogen antibacterial agents. Nat Rev Drug Discov 12: 963. https://doi.org/10.1038/nrd3957-c1.
45. McDonald LC, Banerjee SN, Jarvis WR. 1999. Seasonal variation of Acinetobacter infections: 1987-1996. Nosocomial Infections Surveillance System. Clin Infect Dis 29: 1133-1137.
46. Spellberg B, Bonomo RA. 2013. "Airborne assault": a new dimension in Acinetobacter baumannii transmission. Crit Care Med 41: 2042-2044. https://doi.org/10.1097/CCM.0b013e31829136c3.
47. Whitman TJ, Qasba SS, Timpone JG, Babel BS, Kasper MR, English JF, Sanders JW, Hujer KM, Hujer AM, Endimiani A, Eshoo MW, Bonomo RA. 2008. Occupational transmission of Acinetobacter baumannii from a United States serviceman wounded in Iraq to a health care worker. Clin Infect Dis 47: 439-443. https://doi.org/10.1086/589247.
48. Munoz-Price LS, Fajardo-Aquino Y, Arheart KL, Cleary T, Depascale D, Pizano L, Namias N, Rivera JI, O’Hara JA, Doi Y. 2013. Aerosolization of Acinetobacter baumannii in a trauma ICU. Crit Care Med 41: 1915-1918. https://doi.org/10.1097/CCM.0b013e31828a39c0.
49. Rock C, Harris AD, Johnson JK, Bischoff WE, Thom KA. 2015. Infrequent air contamination with Acinetobacter baumannii of air surrounding known colonized or infected patients. Infect Control Hosp Epidemiol 36: 830-832. https://doi.org/10.1017/ice.2015.68.
50. Freire MP, de Oliveira Garcia D, Garcia CP, Campagnari Bueno MF, Camargo CH, Magri AS, Francisco GR, Reghini R, Vieira MF, Ibrahim KY, Rossi F, Hajar L, Levin AS, Hoff PM, Pierrotti LC, Abdala E. 2016. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. Clin Microbiol Infect 22: 352-358. https://doi.org/10.1016/j.cmi.2015.12.010.
51. Guan X, He L, Hu B, Hu J, Huang X, Lai G, Li Y, Liu Y, Ni Y, Qiu H, Shao Z, Shi Y, Wang M, Wang R, Wu D, Xie C, Xu Y, Yang F, Yu K, Yu Y, Zhang J, Zhuo C, Chinese XDR Consensus Working Group. 2016. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug resistant Gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect 22(Suppl 1): S15-S25. https://doi.org/10.1016/j.cmi.2015.11.004.
52. Chopra T, Marchaim D, Johnson PC, Awali RA, Doshi H, Chalana I, Davis N, Zhao JJ, Pogue JM, Parmar S, Kaye KS. 2014. Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex. Antimicrob Agents Chemother 58: 4630-4635. https://doi.org/10.1128/AAC.02441-14.
53. Chopra T, Marchaim D, Awali RA, Krishna A, Johnson P, Tansek R, Chaudary K, Lephart P, Slim J, Hothi J, Ahmed H, Pogue J, Zhao JJ, Kaye KS. 2013. Epidemiology of bloodstream infection due to Acinetobacter baumannii and the impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes. Antimicrob Agents Chemother 57: 6270-6275. https://doi.org/10.1128/AAC.01520-13.
54. Qiu H, KuoLee R, Harris G, Chen W. 2009. High susceptibility to respiratory Acinetobacter baumannii infection in A/J mice is associated with a delay in early pulmonary recruitment of neutrophils. Microbes Infect 11: 946-955. https://doi.org/10.1016/j.micinf.2009.06.003.
55. Luo G, Lin L, Ibrahim AS, Baquir B, Pantapalangkoor P, Bonomo RA, Doi Y, Adams MD, Russo TA, Spellberg B. 2012. Active and passive immunization protects against lethal, extreme drug resistant-Acinetobacter baumannii infection. PLoS One 7: e29446. https://doi.org/10.1371/ journal.pone.0029446.
56. Luo G, Spellberg B, Gebremariam T, Bolaris M, Lee H, Fu Y, French SW, Ibrahim AS. 2012. Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother 67: 1439-1445. https://doi.org/10.1093/jac/dks050.
57. Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, Sayood K, Iwen PC, Skaar EP, Dunman PM. 2010. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect Immun 78: 1952-1962. https://doi.org/10.1128/IAI.00889-09.
58. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. 1997. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother 41: 345-351.
59. Lopez-Rojas R, Dominguez-Herrera J, McConnell MJ, Docobo-Perez F, Smani Y, Fernandez-Reyes M, Rivas L, Pachon J. 2011. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 203: 545-548. https://doi.org/10.1093/infdis/jiq086.
60. McConnell MJ, Actis L, Pachon J. 2013. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev 37: 130-155. https://doi.org/10.1111/j.1574-6976.2012.00344.x.
61. Kim WY, Moon JY, Huh JW, Choi SH, Lim CM, Koh Y, Chong YP, Hong SB. 2016. Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients. PLoS One 11: e0150642. https://doi.org/10.1371/journal.pone.0150642.
62. Ozvatan T, Akalin H, Sinirtas M, Ocakoglu G, Yilmaz E, Heper Y, Kelebek N, Iscimen R, Kahveci F. 2016. Nosocomial Acinetobacter pneumonia: treatment and prognostic factors in 356 cases. Respirology 21: 363-369. https://doi.org/10.1111/resp.12698.
63. Henig O, Weber G, Hoshen MB, Paul M, German L, Neuberger A, Gluzman I, Berlin A, Shapira C, Balicer RD. 2015. Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case-control study. Eur J Clin Microbiol Infect Dis 34: 2063-2068. https://doi.org/10.1007/s10096-015-2452-4.
64. Nutman A, Glick R, Temkin E, Hoshen M, Edgar R, Braun T, Carmeli Y. 2014. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect 20: O1028-O1034. https://doi.org/10.1111/1469-0691.12716.
65. Ng TM, Teng CB, Lye DC, Apisarnthanarak A. 2014. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 35: 49-55. https://doi.org/10.1086/674387.
66. Zheng YL, Wan YF, Zhou LY, Ye ML, Liu S, Xu CQ, He YQ, Chen JH. 2013. Risk factors and mortality of patients with nosocomial carbapenemresistant Acinetobacter baumannii pneumonia. Am J Infect Control 41: e59-e63. https://doi.org/10.1016/j.ajic.2013.01.006.
67. Arvaniti K, Lathyris D, Ruimy R, Haidich AB, Koulourida V, Nikolaidis P, Matamis D, Miyakis S. 2012. The importance of colonization pressure in multiresistant Acinetobacter baumannii acquisition in a Greek intensive care unit. Crit Care 16: R102. https://doi.org/10.1186/cc11383.
68. Thompson MG, Black CC, Pavlicek RL, Honnold CL, Wise MC, Alamneh YA, Moon JK, Kessler JL, Si Y, Williams R, Yildirim S, Kirkup BC, Jr, Green RK, Hall ER, Palys TJ, Zurawski DV. 2014. Validation of a novel murine wound model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 58: 1332-1342. https://doi.org/10.1128/AAC.01944-13.
69. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock RE, Adams MD, French SW, Buslon VS, Spellberg B. 2012. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 3: e00312-12. https://doi.org/10.1128/mBio.00312-12.
70. Bruhn KW, Pantapalangkoor P, Nielsen T, Tan B, Junus J, Hujer KM, Wright MS, Bonomo RA, Adams MD, Chen W, Spellberg B. 2015. Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia. J Infect Dis 211: 1296-1305. https://doi.org/10.1093/infdis/jiu593.
71. Nielsen TB, Bruhn KW, Pantapalangkoor P, Junus JL, Spellberg B. 2015. Cryopreservation of virulent Acinetobacter baumannii to reduce variability of in vivo studies. BMC Microbiol 15: 252. https://doi.org/10.1186/ s12866-015-0580-8.
72. Lin L, Pantapalangkoor P, Tan B, Bruhn KW, Ho T, Nielsen T, Skaar EP, Zhang Y, Bai R, Wang A, Doherty TM, Spellberg B. 2014. Transferrin iron starvation therapy for lethal bacterial and fungal infections. J Infect Dis 210: 254-264. https://doi.org/10.1093/infdis/jiu049.
73. Russo TA, Beanan JM, Olson R, MacDonald U, Luke NR, Gill SR, Campagnari AA. 2008. Rat pneumonia and soft-tissue infection models for the study of Acinetobacter baumannii biology. Infect Immun 76: 3577-3586. https://doi.org/10.1128/IAI.00269-08.
74. Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, MacDonald U, Schultz LW, Umland TC, Campagnari AA. 2010. The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor. Infect Immun 78: 3993-4000. https://doi.org/10.1128/ IAI.00366-10.
75. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Jr, Mylonakis E. 2009. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 53: 2605-2609. https://doi.org/10.1128/AAC.01533-08.
76. Gebhardt MJ, Gallagher LA, Jacobson RK, Usacheva EA, Peterson LR, Zurawski DV, Shuman HA. 2015. Joint transcriptional control of virulence and resistance to antibiotic and environmental stress in Acinetobacter baumannii. mBio 6: e01660-15. https://doi.org/10.1128/mBio.01660-15.
77. Wand ME, Bock LJ, Turton JF, Nugent PG, Sutton JM. 2012. Acinetobacter baumannii virulence is enhanced in Galleria mellonella following biofilm adaptation. J Med Microbiol 61: 470-477. https://doi.org/10.1099/jmm.0.037523-0.
78. Vallejo JA, Beceiro A, Rumbo-Feal S, Rodriguez-Palero MJ, Russo TA, Bou G. 9 July 2015. Optimisation of the Caenorhabditis elegans model for studying the pathogenesis of opportunistic Acinetobacter baumannii. Int J Antimicrob Agents https://doi.org/10.1016/ j.ijantimicag.2015.05.021.
79. Eijkelkamp BA, Stroeher UH, Hassan KA, Elbourne LD, Paulsen IT, Brown MH. 2013. H-NS plays a role in expression of Acinetobacter baumannii virulence features. Infect Immun 81: 2574-2583. https://doi.org/10.1128/IAI.00065-13.
80. Beceiro A, Moreno A, Fernandez N, Vallejo JA, Aranda J, Adler B, Harper M, Boyce JD, Bou G. 2014. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother 58: 518-526. https://doi.org/10.1128/AAC.01597-13.
81. Bhuiyan MS, Ellett F, Murray GL, Kostoulias X, Cerqueira GM, Schulze KE, Mahamad Maifiah MH, Li J, Creek DJ, Lieschke GJ, Peleg AY. 2016. Acinetobacter baumannii phenylacetic acid metabolism influences infection outcome through a direct effect on neutrophil chemotaxis. Proc Natl Acad Sci U S A 113: 9599-9604. https://doi.org/10.1073/ pnas.1523116113.
82. Zimbler DL, Arivett BA, Beckett AC, Menke SM, Actis LA. 2013. Functional features of TonB energy transduction systems of Acinetobacter baumannii. Infect Immun 81: 3382-3394. https://doi.org/10.1128/IAI.00540-13.
83. Giannouli M, Antunes LC, Marchetti V, Triassi M, Visca P, Zarrilli R. 2013. Virulence-related traits of epidemic Acinetobacter baumannii strains belonging to the international clonal lineages I-III and to the emerging genotypes ST25 and ST78. BMC Infect Dis 13: 282. https://doi.org/10.1186/1471-2334-13-282.
84. Lazaro-Diez M, Navascues-Lejarza T, Remuzgo-Martinez S, Navas J, Icardo JM, Acosta F, Martinez-Martinez L, Ramos-Vivas J. 2016. Acinetobacter baumannii and A. pittii clinical isolates lack adherence and cytotoxicity to lung epithelial cells in vitro. Microbes Infect 18: 559-564. https://doi.org/10.1016/j.micinf.2016.05.002.
85. de Breij A, Eveillard M, Dijkshoorn L, van den Broek PJ, Nibbering PH, Joly-Guillou ML. 2012. Differences in Acinetobacter baumannii strains and host innate immune response determine morbidity and mortality in experimental pneumonia. PLoS One 7: e30673. https://doi.org/10.1371/journal.pone.0030673.
86. Tayabali AF, Nguyen KC, Shwed PS, Crosthwait J, Coleman G, Seligy VL. 2012. Comparison of the virulence potential of Acinetobacter strains from clinical and environmental sources. PLoS One 7: e37024. https:// doi.org/10.1371/journal.pone.0037024.
87. Jacobs AC, Thompson MG, Gebhardt M, Corey BW, Yildirim S, Shuman HA, Zurawski DV. 2014. Genetic manipulation of Acinetobacter baumannii. Curr Protoc Microbiol 35: 6G.2.1-6G.2-11. https://doi.org/10.1002/9780471729259.mc06g02s35.
88. Biswas I. 2015. Genetic tools for manipulating Acinetobacter baumannii genome: an overview. J Med Microbiol 64: 657-669. https://doi.org/10.1099/jmm.0.000081.
89. Wang N, Ozer EA, Mandel MJ, Hauser AR. 2014. Genome-wide identification of Acinetobacter baumannii genes necessary for persistence in the lung. mBio 5: e01163-14. https://doi.org/10.1128/mBio.01163-14.
90. Subashchandrabose S, Smith S, DeOrnellas V, Crepin S, Kole M, Zahdeh C, Mobley HL. 2016. Acinetobacter baumannii genes required for bacterial survival during bloodstream infection. mSphere 1: e00013-15. https://doi.org/10.1128/mSphere.00013-15.
91. Gallagher LA, Ramage E, Weiss EJ, Radey M, Hayden HS, Held KG, Huse HK, Zurawski DV, Brittnacher MJ, Manoil C. 2015. Resources for genetic and genomic analysis of emerging pathogen Acinetobacter baumannii. J Bacteriol 197: 2027-2035. https://doi.org/10.1128/JB.00131-15.
92. Knight D, Dimitrova DD, Rudin SD, Bonomo RA, Rather PN. 2016. Mutations decreasing intrinsic beta-lactam resistance are linked to cell division in the nosocomial pathogen Acinetobacter baumannii. Antimicrob Agents Chemother 60: 3751-3758. https://doi.org/10.1128/ AAC.00361-16.
93. Clemmer KM, Bonomo RA, Rather PN. 2011. Genetic analysis of surface motility in Acinetobacter baumannii. Microbiology 157: 2534-2544. https://doi.org/10.1099/mic.0.049791-0.
94. Smith MG, Des Etages SG, Snyder M. 2004. Microbial synergy via an ethanol-triggered pathway. Mol Cell Biol 24: 3874-3884. https:// doi.org/10.1128/MCB.24.9.3874-3884.2004.
95. Nwugo CC, Arivett BA, Zimbler DL, Gaddy JA, Richards AM, Actis LA. 2012. Effect of ethanol on differential protein production and expression of potential virulence functions in the opportunistic pathogen Acinetobacter baumannii. PLoS One 7: e51936. https://doi.org/10.1371/ journal.pone.0051936.
96. Aranda J, Bardina C, Beceiro A, Rumbo S, Cabral MP, Barbe J, Bou G. 2011. Acinetobacter baumannii RecA protein in repair of DNA damage, antimicrobial resistance, general stress response, and virulence. J Bacteriol 193: 3740-3747. https://doi.org/10.1128/JB.00389-11.
97. Fournier PE, Richet H. 2006. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42: 692-699. https://doi.org/10.1086/500202.
98. Houang ET, Sormunen RT, Lai L, Chan CY, Leong AS. 1998. Effect of desiccation on the ultrastructural appearances of Acinetobacter baumannii and Acinetobacter lwoffii. J Clin Pathol 51: 786-788. https:// doi.org/10.1136/jcp.51.10.786.
99. Wendt C, Dietze B, Dietz E, Ruden H. 1997. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 35: 1394-1397.
100. Schweppe DK, Harding C, Chavez JD, Wu X, Ramage E, Singh PK, Manoil C, Bruce JE. 2015. Host-microbe protein interactions during bacterial infection. Chem Biol 22: 1521-1530. https://doi.org/10.1016/ j.chembiol.2015.09.015.
101. Yoon EJ, Balloy V, Fiette L, Chignard M, Courvalin P, Grillot-Courvalin C. 2016. Contribution of the Ade resistance-nodulation-cell division-type efflux pumps to fitness and pathogenesis of Acinetobacter baumannii. mBio 7: e00697-16. https://doi.org/10.1128/mBio.00697-16.
102. Bonomo RA, Szabo D. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43(Suppl 2): S49-S56. https://doi.org/10.1086/504477.
103. Richmond GE, Evans LP, Anderson MJ, Wand ME, Bonney LC, Ivens A, Chua KL, Webber MA, Sutton JM, Peterson ML, Piddock LJ. 2016. The Acinetobacter baumannii two-component system AdeRS regulates genes required for multidrug efflux, biofilm formation, and virulence in a strain-specific manner. mBio 7: e00430-16. https://doi.org/10.1128/ mBio.00430-16.
104. Luke NR, Sauberan SL, Russo TA, Beanan JM, Olson R, Loehfelm TW, Cox AD, St Michael F, Vinogradov EV, Campagnari AA. 2010. Identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis. Infect Immun 78: 2017-2023. https://doi.org/10.1128/IAI.00016-10.
105. Lees-Miller R, Iwashkiw J, Scott NE, Seper A, Vinogradov E, Schild S, Feldman M. 2013. A common pathway for O-linked proteinglycosylation and synthesis of capsule in Acinetobacter baumannii. Mol Microbiol 89: 816-830. https://doi.org/10.1111/mmi.12300.
106. Weber BS, Harding CM, Feldman MF. 2015. Pathogenic Acinetobacter: from the cell surface to infinity and beyond. J Bacteriol 198: 880-887. https://doi.org/10.1128/JB.00906-15.
107. Geisinger E, Isberg RR. 2015. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog 11: e1004691. https://doi.org/10.1371/journal.ppat.1004691.
108. Jones CL, Clancy M, Honnold C, Singh S, Snesrud E, Onmus-Leone F, McGann P, Ong A, Kwak Y, Waterman P, Zurawski DV, Clifford RJ, Lesho E. 2015. A fatal outbreak of an emerging clone of extensively drugresistant Acinetobacter baumannii with enhanced virulence. Clin Infect Dis 61: 145-154. https://doi.org/10.1093/cid/civ225.
109. Ou HY, Kuang SN, He X, Molgora BM, Ewing PJ, Deng Z, Osby M, Chen W, Xu HH. 2015. Complete genome sequence of hypervirulent and outbreak-associated Acinetobacter baumannii strain LAC-4: epidemiology, resistance genetic determinants and potential virulence factors. Sci Rep 5: 8643. https://doi.org/10.1038/srep08643.
110. Vinogradov E, MacLean L, Xu HH, Chen W. 2014. The structure of the polysaccharide isolated from Acinetobacter baumannii strain LAC-4. Carbohydr Res 390: 42-45. https://doi.org/10.1016/j.carres.2014.03.001.
111. Scott NE, Kinsella RL, Edwards AV, Larsen MR, Dutta S, Saba J, Foster LJ, Feldman MF. 2014. Diversity within the O-linked protein glycosylation systems of Acinetobacter species. Mol Cell Proteomics 13: 2354-2370. https://doi.org/10.1074/mcp.M114.038315.
112. Kinsella RL, Scott NE, Feldman MF. 2015. Clinical implications of glycoproteomics for Acinetobacter baumannii. Expert Rev Proteomics 12: 1-3. https://doi.org/10.1586/14789450.2015.987756.
113. Russo TA, Beanan JM, Olson R, MacDonald U, Cox AD, St Michael F, Vinogradov EV, Spellberg B, Luke-Marshall NR, Campagnari AA. 2013. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun 81: 915-922. https://doi.org/10.1128/IAI.01184-12.
114. Shashkov AS, Kenyon JJ, Senchenkova SN, Shneider MM, Popova AV, Arbatsky NP, Miroshnikov KA, Volozhantsev NV, Hall RM, Knirel YA. 2016. Acinetobacter baumannii K27 and K44 capsular polysaccharides have the same K unit but different structures due to the presence of distinct wzy genes in otherwise closely related K gene clusters. Glycobiology 26: 501-508. https://doi.org/10.1093/glycob/cwv168.
115. Kenyon JJ, Shneider MM, Senchenkova SN, Shashkov AS, Siniagina MN, Malanin SY, Popova AV, Miroshnikov KA, Hall RM, Knirel YA. 2016. The K19 capsular polysaccharide of Acinetobacter baumannii is produced via a Wzy polymerase encoded in a small genomic island rather than the KL19 capsule gene cluster. Microbiology 162: 1479-1489. https:// doi.org/10.1099/mic.0.000313.
116. Kenyon JJ, Speciale I, Hall RM, De Castro C. 2016. Structure of repeating unit of the capsular polysaccharide from Acinetobacter baumannii D78 and assignment of the K4 gene cluster. Carbohydr Res 434: 12-17. https://doi.org/10.1016/j.carres.2016.07.016.
117. van Faassen H, KuoLee R, Harris G, Zhao X, Conlan JW, Chen W. 2007. Neutrophils play an important role in host resistance to respiratory infection with Acinetobacter baumannii in mice. Infect Immun 75: 5597-5608. https://doi.org/10.1128/IAI.00762-07.
118. Breslow JM, Meissler JJ, Jr, Hartzell RR, Spence PB, Truant A, Gaughan J, Eisenstein TK. 2011. Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not IL-17, mediate host resistance. Infect Immun 79: 3317-3327. https://doi.org/10.1128/ IAI.00069-11.
119. Qiu H, Kuolee R, Harris G, Chen W. 2009. Role of NADPH phagocyte oxidase in host defense against acute respiratory Acinetobacter baumannii infection in mice. Infect Immun 77: 1015-1021. https://doi.org/10.1128/IAI.01029-08.
120. Qiu H, Kuolee R, Harris G, Van Rooijen N, Patel GB, Chen W. 2012. Role of macrophages in early host resistance to respiratory Acinetobacter baumannii infection. PLoS One 7: e40019. https://doi.org/10.1371/ journal.pone.0040019.
121. Hood MI, Uzhachenko R, Boyd K, Skaar EP, Ivanova AV. 2013. Loss of mitochondrial protein Fus1 augments host resistance to Acinetobacter baumannii infection. Infect Immun 81: 4461-4469. https://doi.org/10.1128/IAI.00771-13.
122. Garcia A, Salgado F, Solar H, Gonzalez CL, Zemelman R, Onate A. 1999. Some immunological properties of lipopolysaccharide from Acinetobacter baumannii. J Med Microbiol 48: 479-483. https://doi.org/10.1099/00222615-48-5-479.
123. Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR. 2007. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. J Med Microbiol 56: 165-171. https://doi.org/10.1099/jmm.0.46823-0.
124. Knapp S, Wieland CW, Florquin S, Pantophlet R, Dijkshoorn L, Tshimbalanga N, Akira S, van der Poll T. 2006. Differential roles of CD14 and Toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am J Respir Crit Care Med 173: 122-129. https://doi.org/10.1164/ rccm.200505-730OC.
125. Renckens R, Roelofs JJ, Knapp S, de Vos AF, Florquin S, van der Poll T. 2006. The acute-phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter baumannii pneumonia. J Infect Dis 193: 187-195. https://doi.org/10.1086/498876.
126. Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, Gancz HY, Corey BW, Moon JK, Si Y, Owen MT, Hallock JD, Kwak YI, Summers A, Li CZ, Rasko DA, Penwell WF, Honnold CL, Wise MC, Waterman PE, Lesho EP, Stewart RL, Actis LA, Palys TJ, Craft DW, Zurawski DV. 2014. AB5075, a highly virulent isolate of Acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. mBio 5: e01076-14. https://doi.org/10.1128/ mBio.01076-14.
127. Infectious Diseases Society of America. 2012. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 55: 1031-1046. https://doi.org/10.1093/cid/cis688.
128. Harris G, Kuo Lee R, Lam CK, Kanzaki G, Patel GB, Xu HH, Chen W. 2013. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother 57: 3601-3613. https://doi.org/10.1128/AAC.00944-13.
129. Noto MJ, Boyd KL, Burns WJ, Varga MG, Peek RM, Jr, Skaar EP. 2015. Toll-like receptor 9 contributes to defense against Acinetobacter baumannii infection. Infect Immun 83: 4134-4141. https://doi.org/10.1128/ IAI.00410-15.
130. Breslow JM, Monroy MA, Daly JM, Meissler JJ, Gaughan J, Adler MW, Eisenstein TK. 2011. Morphine, but not trauma, sensitizes to systemic Acinetobacter baumannii infection. J Neuroimmune Pharmacol 6: 551-565. https://doi.org/10.1007/s11481-011-9303-6.
131. Banerjee S, Meng J, Das S, Krishnan A, Haworth J, Charboneau R, Zeng Y, Ramakrishnan S, Roy S. 2013. Morphine induced exacerbation of sepsis is mediated by tempering endotoxin tolerance through modulation of miR-146a. Sci Rep 3: 1977. https://doi.org/10.1038/srep01977.
132. Roux D, Danilchanka O, Guillard T, Cattoir V, Aschard H, Fu Y, Angoulvant F, Messika J, Ricard JD, Mekalanos JJ, Lory S, Pier GB, Skurnik D. 2015. Fitness cost of antibiotic susceptibility during bacterial infection. Sci Transl Med 7: 297ra114. https://doi.org/10.1126/scitranslmed.aab1621.
133. Vila J, Marti S, Sanchez-Cespedes J. 2007. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 59: 1210-1215. https://doi.org/10.1093/jac/dkl509.
134. Sato K, Nakae T. 1991. Outer membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic resistance. J Antimicrob Chemother 28: 35-45. https://doi.org/10.1093/jac/28.1.35.
135. Adams MD, Goglin K, Molyneaux N, Hujer KM, Lavender H, Jamison JJ, MacDonald IJ, Martin KM, Russo T, Campagnari AA, Hujer AM, Bonomo RA, Gill SR. 2008. Comparative genome sequence analysis of multidrugresistant Acinetobacter baumannii. J Bacteriol 190: 8053-8064. https:// doi.org/10.1128/JB.00834-08.
136. Blackwell GA, Hamidian M, Hall RM. 2016. IncM plasmid R1215 is the source of chromosomally located regions containing multiple antibiotic resistance genes in the globally disseminated Acinetobacter baumannii GC1 and GC2 clones. mSphere 1: e00117-16. https://doi.org/10.1128/mSphere.00117-16.
137. Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ, Liao CH, Hsueh PR, Yang JL, Shen NJ, Wang JT, Hung CC, Chen YC, Chang SC. 2015. Excess mortality associated with colistin-tigecycline compared with colistincarbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med 43: 1194-1204. https://doi.org/10.1097/ CCM.0000000000000933.
138. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. 2003. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 51: 565-574. https://doi.org/10.1093/ jac/dkg097.
139. D’Arezzo S, Capone A, Petrosillo N, Visca P, Ballardini M, Bartolini S, Bordi E, Di Stefano A, Galie M, Minniti R, Meledandri M, Pacciani L, Parisi G, Prignano G, Santini C, Valmarin M, Venditti M, Ziantoni S. 2009. Epidemic multidrug-resistant Acinetobacter baumannii related to European clonal types I and II in Rome (Italy). Clin Microbiol Infect 15: 347-357. https://doi.org/10.1111/j.1469-0691.2009.02668.x.
140. Higgins PG, Dammhayn C, Hackel M, Seifert H. 2010. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 65: 233-238. https://doi.org/10.1093/jac/dkp428.
141. Adams-Haduch JM, Onuoha EO, Bogdanovich T, Tian GB, Marschall J, Urban CM, Spellberg BJ, Rhee D, Halstead DC, Pasculle AW, Doi Y. 2011. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol 49: 3849-3854. https:// doi.org/10.1128/JCM.00619-11.
142. Ben RJ, Yang MC, Hsueh JC, Shiang JC, Chien ST. 2011. Molecular characterisation of multiple drug-resistant Acinetobacter baumannii isolates in southern Taiwan. Int J Antimicrob Agents 38: 403-408. https://doi.org/10.1016/j.ijantimicag.2011.05.014.
143. Wu W, He Y, Lu J, Lu Y, Wu J, Liu Y. 2015. Transition of blaOXA-58-like to blaOXA-23-like in Acinetobacter baumannii clinical isolates in southern China: an 8-year study. PLoS One 10: e0137174. https://doi.org/10.1371/journal.pone.0137174.
144. Kamolvit W, Sidjabat HE, Paterson DL. 2015. Molecular epidemiology and mechanisms of carbapenem resistance of Acinetobacter spp. in Asia and Oceania. Microb Drug Resist 21: 424-434. https://doi.org/10.1089/mdr.2014.0234.
145. Principe L, Piazza A, Giani T, Bracco S, Caltagirone MS, Arena F, Nucleo E, Tammaro F, Rossolini GM, Pagani L, Luzzaro F, AMCLI-CRAb Survey Participants. 2014. Epidemic diffusion of OXA-23-producing Acinetobacter baumannii isolates in Italy: results of the first cross-sectional countrywide survey. J Clin Microbiol 52: 3004-3010. https://doi.org/10.1128/JCM.00291-14.
146. Ji S, Chen Y, Ruan Z, Fu Y, Ji J, Fu Y, Wang H, Yu Y. 2014. Prevalence of carbapenem-hydrolyzing class D beta-lactamase genes in Acinetobacter spp. isolates in China. Eur J Clin Microbiol Infect Dis 33: 989-997. https://doi.org/10.1007/s10096-013-2037-z.
147. Zarrilli R, Pournaras S, Giannouli M, Tsakris A. 2013. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents 41: 11-19. https://doi.org/10.1016/ j.ijantimicag.2012.09.008.
148. Nigro SJ, Hall RM. 2016. Structure and context of Acinetobacter transposons carrying the oxa23 carbapenemase gene. J Antimicrob Chemother 71: 1135-1147. https://doi.org/10.1093/jac/dkv440.
149. Nigro S, Hall RM. 2015. Distribution of the blaOXA-23-containing transposons Tn2006 and Tn2008 in Australian carbapenem-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 70: 2409-2411. https://doi.org/10.1093/jac/dkv102.
150. Liu LL, Ji SJ, Ruan Z, Fu Y, Fu YQ, Wang YF, Yu YS. 2015. Dissemination of blaOXA-23 in Acinetobacter spp. in China: main roles of conjugative plasmid pAZJ221 and transposon Tn2009. Antimicrob Agents Chemother 59: 1998-2005. https://doi.org/10.1128/AAC.04574-14.
151. Warner WA, Kuang SN, Hernandez R, Chong MC, Ewing PJ, Fleischer J, Meng J, Chu S, Terashita D, English L, Chen W, Xu HH. 2016. Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA. BMC Infect Dis 16: 194. https://doi.org/10.1186/ s12879-016-1526-y.
152. Agodi A, Voulgari E, Barchitta M, Quattrocchi A, Bellocchi P, Poulou A, Santangelo C, Castiglione G, Giaquinta L, Romeo MA, Vrioni G, Tsakris A. 2014. Spread of a carbapenem-and colistin-resistant Acinetobacter baumannii ST2 clonal strain causing outbreaks in two Sicilian hospitals. J Hosp Infect 86: 260-266. https://doi.org/10.1016/j.jhin.2014.02.001.
153. Lee HY, Chen CL, Wu SR, Huang CW, Chiu CH. 2014. Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med 42: 1081-1088. https://doi.org/10.1097/ CCM.0000000000000125.
154. Song JY, Cheong HJ, Choi WS, Heo JY, Noh JY, Kim WJ. 2011. Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections. J Med Microbiol 60: 605-611. https://doi.org/10.1099/jmm.0.029439-0.
155. Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y. 2008. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 52: 3837-3843. https://doi.org/10.1128/AAC.00570-08.
156. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51: 3471-3484. https://doi.org/10.1128/ AAC.01464-06.
157. Dortet L, Poirel L, Errera C, Nordmann P. 2014. CarbAcineto NP test for rapid detection of carbapenemase-producing Acinetobacter spp. J Clin Microbiol 52: 2359-2364. https://doi.org/10.1128/JCM.00594-14.
158. Bonnin RA, Poirel L, Naas T, Pirs M, Seme K, Schrenzel J, Nordmann P. 2012. Dissemination of New Delhi metallo-beta-lactamase-1-producing Acinetobacter baumannii in Europe. Clin Microbiol Infect 18: E362-E365. https://doi.org/10.1111/j.1469-0691.2012.03928.x.
159. Krahn T, Wibberg D, Maus I, Winkler A, Bontron S, Sczyrba A, Nordmann P, Puhler A, Poirel L, Schluter A. 2016. Intraspecies transfer of the chromosomal Acinetobacter baumannii blaNDM-1 carbapenemase gene. Antimicrob Agents Chemother 60: 3032-3040. https://doi.org/10.1128/AAC.00124-16.
160. Bonnin RA, Poirel L, Nordmann P. 2014. New Delhi metallo-betalactamase-producing Acinetobacter baumannii: a novel paradigm for spreading antibiotic resistance genes. Future Microbiol 9: 33-41. https://doi.org/10.2217/fmb.13.69.
161. Bonnin RA, Nordmann P, Potron A, Lecuyer H, Zahar JR, Poirel L. 2011. Carbapenem-hydrolyzing GES-type extended-spectrum beta-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 55: 349-354. https://doi.org/10.1128/AAC.00773-10.
162. Moubareck C, Bremont S, Conroy MC, Courvalin P, Lambert T. 2009. GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob Agents Chemother 53: 3579-3581. https://doi.org/10.1128/AAC.00072-09.
163. Castanheira M, Costello SE, Woosley LN, Deshpande LM, Davies TA, Jones RN. 2014. Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel betalactamases, GES-22 and VIM-35. Antimicrob Agents Chemother 58: 7358-7366. https://doi.org/10.1128/AAC.03930-14.
164. Robledo IE, Aquino EE, Sante MI, Santana JL, Otero DM, Leon CF, Vazquez GJ. 2010. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother 54: 1354-1357. https://doi.org/10.1128/AAC.00899-09.
165. Robledo IE, Aquino EE, Vazquez GJ. 2011. Detection of the KPC gene in Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii during a PCR-based nosocomial surveillance study in Puerto Rico. Antimicrob Agents Chemother 55: 2968-2970. https://doi.org/10.1128/AAC.01633-10.
166. Mussi MA, Limansky AS, Viale AM. 2005. Acquisition of resistance to carbapenems in multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrob Agents Chemother 49: 1432-1440. https://doi.org/10.1128/ AAC.49.4.1432-1440.2005.
167. Siroy A, Molle V, Lemaitre-Guillier C, Vallenet D, Pestel-Caron M, Cozzone AJ, Jouenne T, De E. 2005. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrob Agents Chemother 49: 4876-4883. https://doi.org/10.1128/AAC.49.12.4876-4883.2005.
168. Dupont M, Pages JM, Lafitte D, Siroy A, Bollet C. 2005. Identification of an OprD homologue in Acinetobacter baumannii. J Proteome Res 4: 2386-2390. https://doi.org/10.1021/pr050143q.
169. Catel-Ferreira M, Coadou G, Molle V, Mugnier P, Nordmann P, Siroy A, Jouenne T, De E. 2011. Structure-function relationships of CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. J Antimicrob Chemother 66: 2053-2056. https:// doi.org/10.1093/jac/dkr267.
170. Fonseca EL, Scheidegger E, Freitas FS, Cipriano R, Vicente AC. 2013. Carbapenem-resistant Acinetobacter baumannii from Brazil: role of carO alleles expression and blaOXA-23 gene. BMC Microbiol 13: 245. https://doi.org/10.1186/1471-2180-13-245.
171. Smani Y, Dominguez-Herrera J, Pachon J. 2013. Association of the outer membrane protein Omp33 with fitness and virulence of Acinetobacter baumannii. J Infect Dis 208: 1561-1570. https://doi.org/10.1093/infdis/ jit386.
172. McGann P, Courvalin P, Snesrud E, Clifford RJ, Yoon EJ, Onmus-Leone F, Ong AC, Kwak YI, Grillot-Courvalin C, Lesho E, Waterman PE. 2014. Amplification of aminoglycoside resistance gene aphA1 in Acinetobacter baumannii results in tobramycin therapy failure. mBio 5: e00915. https://doi.org/10.1128/mBio.00915-14.
173. Martinez T, Martinez I, Vazquez GJ, Aquino EE, Robledo IE. 2016. Genetic environment of the KPC gene in Acinetobacter baumannii ST2 clone from Puerto Rico and genomic insights into its drug resistance. J Med Microbiol 65: 784-792. https://doi.org/10.1099/jmm.0.000289.
174. Mosqueda N, Espinal P, Cosgaya C, Viota S, Plasensia V, Alvarez-Lerma F, Montero M, Gomez J, Horcajada JP, Vila J, Roca I. 2013. Globally expanding carbapenemase finally appears in Spain: nosocomial outbreak of Acinetobacter baumannii producing plasmid-encoded OXA-23 in Barcelona, Spain. Antimicrob Agents Chemother 57: 5155-5157. https://doi.org/10.1128/AAC.01486-13.
175. Hamidian M, Hall RM. 2014. pACICU2 is a conjugative plasmid of Acinetobacter carrying the aminoglycoside resistance transposon TnaphA6. J Antimicrob Chemother 69: 1146-1148. https://doi.org/10.1093/ jac/dkt488.
176. Hamidian M, Hall RM. 2014. Tn6168, a transposon carrying an ISAba1-activated ampC gene and conferring cephalosporin resistance in Acinetobacter baumannii. J Antimicrob Chemother 69: 77-80. https:// doi.org/10.1093/jac/dkt312.
177. Hamidian M, Holt KE, Pickard D, Dougan G, Hall RM. 2014. A GC1 Acinetobacter baumannii isolate carrying AbaR3 and the aminoglycoside resistance transposon TnaphA6 in a conjugative plasmid. J Antimicrob Chemother 69: 955-958. https://doi.org/10.1093/jac/dkt454.
178. Guerrero-Lozano I, Fernandez-Cuenca F, Galan-Sanchez F, Egea P, Rodriguez-Iglesias M, Pascual A. 2015. Description of the OXA-23 betalactamase gene located within Tn2007 in a clinical isolate of Acinetobacter baumannii from Spain. Microb Drug Resist 21: 215-217. https:// doi.org/10.1089/mdr.2014.0155.
179. Blot S, Vandewoude K, Colardyn F. 2003. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: a matched cohort study. Intensive Care Med 29: 471-475. https://doi.org/10.1007/ s00134-003-1648-8.
180. Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. 2016. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit Care 20: 221. https://doi.org/10.1186/s13054-016-1392-4.
181. Shlaes DM, Moellering RC, Jr. 2002. The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis 34: 420-422. https://doi.org/10.1086/334577.
182. Zilberberg MD, Kollef MH, Shorr AF. 2016. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med 11: 21-26. https://doi.org/10.1002/jhm.2477.
183. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. 2009. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol 30: 1186-1192. https://doi.org/10.1086/648450.
184. Agodi A, Barchitta M, Quattrocchi A, Maugeri A, Aldisio E, Marchese AE, Mattaliano AR, Tsakris A. 2015. Antibiotic trends of Klebsiella pneumoniae and Acinetobacter baumannii resistance indicators in an intensive care unit of Southern Italy, 2008-2013. Antimicrob Resist Infect Control 4: 43. https://doi.org/10.1186/s13756-015-0087-y.
185. Gales AC, Castanheira M, Jones RN, Sader HS. 2012. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 73: 354-360. https://doi.org/10.1016/j.diagmicrobio.2012.04.007.
186. Taneja N, Singh G, Singh M, Sharma M. 2011. Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. Indian J Med Res 133: 681-684.
187. Perween N, Sehgal S, Prakash SK. 2014. Geographical patterns in antimicrobial resistance of Acinetobacter in clinical isolates. J Clin Diagn Res 8: DC10-DC12. https://doi.org/10.7860/JCDR/2014/8590.4235.
188. Gandra S, Mojica N, Klein EY, Ashok A, Nerurkar V, Kumari M, Ramesh U, Dey S, Vadwai V, Das BR, Laxminarayan R. 2016. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008-2014. Int J Infect Dis 50: 75-82. https://doi.org/10.1016/j.ijid.2016.08.002.
189. Tsioutis C, Kritsotakis EI, Karageorgos SA, Stratakou S, Psarologakis C, Kokkini S, Gikas A. 12 August 2016. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. Int J Antimicrob Agents https://doi.org/10.1016/j.ijantimicag.2016.07.007.
190. Guo H, Qin J, Xiang J. 17 August 2016. Surveillance for and susceptibility of Acinetobacter baumannii in a large hospital and burn center in Shanghai, China, 2007-2013. Am J Infect Control https://doi.org/10.1016/j.ajic.2016.06.014.
191. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH. 2011. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 55: 4844-4849. https://doi.org/10.1128/AAC.01728-10.
192. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302: 2323-2329. https://doi.org/10.1001/jama.2009.1754.
193. Leao AC, Menezes PR, Oliveira MS, Levin AS. 2016. Acinetobacter spp. are associated with a higher mortality in intensive care patients with bacteremia: a survival analysis. BMC Infect Dis 16: 386. https://doi.org/10.1186/s12879-016-1695-8.
194. Raad II, Mohamed JA, Reitzel RA, Jiang Y, Dvorak TL, Ghannoum MA, Hachem RY, Chaftari AM. 2011. The prevention of biofilm colonization by multidrug-resistant pathogens that cause ventilator-associated pneumonia with antimicrobial-coated endotracheal tubes. Biomaterials 32: 2689-2694. https://doi.org/10.1016/j.biomaterials.2010.12.015.
195. Gil-Perotin S, Ramirez P, Marti V, Sahuquillo JM, Gonzalez E, Calleja I, Menendez R, Bonastre J. 2012. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Crit Care 16: R93. https://doi.org/10.1186/cc11357.
196. Davis KA, Moran KA, McAllister CK, Gray PJ. 2005. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 11: 1218-1224. https://doi.org/10.3201/1108.050103.
197. Yun HC, Branstetter JG, Murray CK. 2008. Osteomyelitis in military personnel wounded in Iraq and Afghanistan. J Trauma 64: S163-S168. https://doi.org/10.1097/TA.0b013e318160868c.
198. Carvalho VC, Oliveira PR, Dal-Paz K, Paula AP, Felix CDS, Lima AL. 2012. Gram-negative osteomyelitis: clinical and microbiological profile. Braz J Infect Dis 16: 63-67. https://doi.org/10.1016/S1413-8670(12)70276-3.
199. Falagas ME, Karveli EA, Kelesidis I, Kelesidis T. 2007. Communityacquired Acinetobacter infections. Eur J Clin Microbiol Infect Dis 26: 857-868. https://doi.org/10.1007/s10096-007-0365-6.
200. Peng C, Zong Z, Fan H. 2012. Acinetobacter baumannii isolates asso-ciated with community-acquired pneumonia in West China. Clin Microbiol Infect 18: E491-E493. https://doi.org/10.1111/1469-0691.12017.
201. Anstey NM, Currie BJ, Hassell M, Palmer D, Dwyer B, Seifert H. 2002. Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol 40: 685-686. https://doi.org/10.1128/JCM.40.2.685-686.2002.
202. O’Shea MK. 2012. Acinetobacter in modern warfare. Int J Antimicrob Agents 39: 363-375. https://doi.org/10.1016/j.ijantimicag.2012.01.018.
203. Murray CK, Roop SA, Hospenthal DR, Dooley DP, Wenner K, Hammock J, Taufen N, Gourdine E. 2006. Bacteriology of war wounds at the time of injury. Mil Med 171: 826-829. https://doi.org/10.7205/ MILMED.171.9.826.
204. Murray CK, Wilkins K, Molter NC, Yun HC, Dubick MA, Spott MA, Jenkins D, Eastridge B, Holcomb JB, Blackbourne LH, Hospenthal DR. 2009. Infections in combat casualties during Operations Iraqi and Enduring Freedom. J Trauma 66: S138-S144. https://doi.org/10.1097/TA.0b013e31819d894c.
205. Murray CK, Yun HC, Griffith ME, Thompson B, Crouch HK, Monson LS, Aldous WK, Mende K, Hospenthal DR. 2009. Recovery of multidrugresistant bacteria from combat personnel evacuated from Iraq and Afghanistan at a single military treatment facility. Mil Med 174: 598-604. https://doi.org/10.7205/MILMED-D-03-8008.
206. Petersen K, Riddle MS, Danko JR, Blazes DL, Hayden R, Tasker SA, Dunne JR. 2007. Trauma-related infections in battlefield casualties from Iraq. Ann Surg 245: 803-811. https://doi.org/10.1097/01.sla.0000251707.32332.c1.
207. Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, Fishbain J, Craft D, Riddell S, Lindler L, Mancuso J, Milstrey E, Bautista CT, Patel J, Ewell A, Hamilton T, Gaddy C, Tenney M, Christopher G, Petersen K, Endy T, Petruccelli B. 2007. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis 44: 1577-1584. https://doi.org/10.1086/518170.
208. Centers for Disease Control and Prevention. 2004. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.. service members, 2002-2004. MMWR Morb Mortal Wkly Rep 53: 1063-1066.
209. Oncul O, Keskin O, Acar HV, Kucukardali Y, Evrenkaya R, Atasoyu EM, Top C, Nalbant S, Ozkan S, Emekdas G, Cavuslu S, Us MH, Pahsa A, Gokben M. 2002. Hospital-acquired infections following the 1999 Marmara earthquake. J Hosp Infect 51: 47-51. https://doi.org/10.1053/ jhin.2002.1205.
210. Maegele M, Gregor S, Steinhausen E, Bouillon B, Heiss MM, Perbix W, Wappler F, Rixen D, Geisen J, Berger-Schreck B, Schwarz R. 2005. The long-distance tertiary air transfer and care of tsunami victims: injury pattern and microbiological and psychological aspects. Crit Care Med 33: 1136-1140. https://doi.org/10.1097/01.CCM.0000163269.42524.50.
211. Tao C, Kang M, Chen Z, Xie Y, Fan H, Qin L, Ma Y. 2009. Microbiologic study of the pathogens isolated from wound culture among Wenchuan earthquake survivors. Diagn Microbiol Infect Dis 63: 268-270. https:// doi.org/10.1016/j.diagmicrobio.2008.11.009.
212. Dallo SF, Weitao T. 2010. Insights into Acinetobacter war-wound infections, biofilms, and control. Adv Skin Wound Care 23: 169-174. https:// doi.org/10.1097/01.ASW.0000363527.08501.a3.
213. Wang Y, Hao P, Lu B, Yu H, Huang W, Hou H, Dai K. 2010. Causes of infection after earthquake, China, 2008. Emerg Infect Dis 16: 974-975. https://doi.org/10.3201/eid1606.091523.
214. Zhang B, Liu Z, Lin Z, Zhang X, Fu W. 2012. Microbiologic characteristics of pathogenic bacteria from hospitalized trauma patients who survived Wenchuan earthquake. Eur J Clin Microbiol Infect Dis 31: 2529-2535. https://doi.org/10.1007/s10096-012-1591-0.
215. Apisarnthanarak A, Khawcharoenporn T, Mundy LM. 2013. Patterns of nosocomial infections, multidrug-resistant microorganisms, and mold detection after extensive black-water flooding: a survey from central Thailand. Infect Control Hosp Epidemiol 34: 861-863. https://doi.org/10.1086/671277.
216. Nonaka Y, Nagae M, Omae T, Yamamoto S, Horitani R, Maeda D, Yoshinaga T. 2014. Community-acquired necrotizing fasciitis caused by Acinetobacter calcoaceticus: a case report and literature review. J Infect Chemother 20: 330-335. https://doi.org/10.1016/j.jiac.2013.12.011.
217. Sinha N, Niazi M, Lvovsky D. 2014. A fatal case of multidrug resistant Acinetobacter necrotizing fasciitis: the changing scary face of nosocomial infection. Case Rep Infect Dis 2014: 705279. https://doi.org/10.1155/2014/705279.
218. Corradino B, Toia F, di Lorenzo S, Cordova A, Moschella F. 2010. A difficult case of necrotizing fasciitis caused by Acinetobacter baumannii. Int J Low Extrem Wounds 9: 152-154. https://doi.org/10.1177/1534734610389598.
219. Clemente WT, Sanches MD, Coutinho RL, de Oliveira Junior AR, Lauria MW, Lima CX, de Castro Romanelli RM. 2012. Multidrug-resistant Acinetobacter baumannii causing necrotizing fasciitis in a pancreas-kidney transplant recipient: a case report. Transplantation 94: e37-e38. https:// doi.org/10.1097/TP.0b013e318265083b.
220. Sullivan DR, Shields J, Netzer G. 2010. Fatal case of multi-drug resistant Acinetobacter baumannii necrotizing fasciitis. Am Surg 76: 651-653.
221. Charnot-Katsikas A, Dorafshar AH, Aycock JK, David MZ, Weber SG, Frank KM. 2009. Two cases of necrotizing fasciitis due to Acinetobacter baumannii. J Clin Microbiol 47: 258-263. https://doi.org/10.1128/ JCM.01250-08.
222. Brachelente C, Wiener D, Malik Y, Huessy D. 2007. A case of necrotizing fasciitis with septic shock in a cat caused by Acinetobacter baumannii. Vet Dermatol 18: 432-438. https://doi.org/10.1111/j.1365-3164.2007.00624.x.
223. Pailhories H, Belmonte O, Kempf M, Lemarie C, Cuziat J, Quinqueneau C, Ramont C, Joly-Guillou ML, Eveillard M. 2015. Diversity of Acinetobacter baumannii strains isolated in humans, companion animals, and the environment in Reunion Island: an exploratory study. Int J Infect Dis 37: 64-69. https://doi.org/10.1016/j.ijid.2015.05.012.
224. Belmonte O, Pailhories H, Kempf M, Gaultier MP, Lemarie C, Ramont C, Joly-Guillou ML, Eveillard M. 2014. High prevalence of closely-related Acinetobacter baumannii in pets according to a multicentre study in veterinary clinics, Reunion Island. Vet Microbiol 170: 446-450. https:// doi.org/10.1016/j.vetmic.2014.01.042.
225. Zordan S, Prenger-Berninghoff E, Weiss R, van der Reijden T, van den Broek P, Baljer G, Dijkshoorn L. 2011. Multidrug-resistant Acinetobacter baumannii in veterinary clinics, Germany. Emerg Infect Dis 17: 1751-1754. https://doi.org/10.3201/eid1709.101931.
226. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. 2004. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 26: 1187-1198. https://doi.org/10.1016/S0149-2918(04)80001-8.
227. Lomaestro BM, Drusano GL. 2005. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 49: 461-463. https://doi.org/10.1128/AAC.49.1.461-463.2005.
228. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sorgel F, Jones RN, Drusano GL, Bertino JS, Jr. 2010. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 68: 251-258. https:// doi.org/10.1016/j.diagmicrobio.2010.06.012.
229. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. 2013. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56: 272-282. https://doi.org/10.1093/cid/ cis857.
230. Prasad P, Sun J, Danner RL, Natanson C. 2012. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54: 1699-1709. https://doi.org/10.1093/cid/cis270.
231. Gardiner D, Dukart G, Cooper A, Babinchak T. 2010. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 50: 229-238. https://doi.org/10.1086/648720.
232. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H, 311 Study Group. 2010. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospitalacquired pneumonia. Diagn Microbiol Infect Dis 68: 140-151. https://doi.org/10.1016/j.diagmicrobio.2010.05.012.
233. Spellberg B, Bonomo RA. 2015. Combination therapy for extreme drugresistant Acinetobacter baumannii: ready for prime time? Crit Care Med 43: 1332-1334. https://doi.org/10.1097/CCM.0000000000001029.
234. Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, Chang SC. 2014. Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 14: 102. https://doi.org/10.1186/1471-2334-14-102.
235. Lee YT, Tsao SM, Hsueh PR. 2013. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 32: 1211-1220. https://doi.org/10.1007/s10096-013-1870-4.
236. Gordon NC, Wareham DW. 2009. A review of clinical and microbiological outcomes following treatment of infections involving multidrugresistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 63: 775-780. https://doi.org/10.1093/jac/dkn555.
237. Ni W, Han Y, Zhao J, Wei C, Cui J, Wang R, Liu Y. 2016. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents 47: 107-116. https://doi.org/10.1016/j.ijantimicag.2015.11.011.
238. Goff DA, Kaye KS. 2014. Minocycline: an old drug for a new bug: multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 59(Suppl 6): S365-S366. https://doi.org/10.1093/cid/ciu531.
239. Ritchie DJ, Garavaglia-Wilson A. 2014. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 59(Suppl 6): S374-S380. https://doi.org/10.1093/cid/ ciu613.
240. Goff DA, Bauer KA, Mangino JE. 2014. Bad bugs need old drugs: a stewardship program’s evaluation of minocycline for multidrugresistant Acinetobacter baumannii infections. Clin Infect Dis 59(Suppl 6): S381-S387. https://doi.org/10.1093/cid/ciu593.
241. Flamm RK, Castanheira M, Streit JM, Jones RN. 2016. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagn Microbiol Infect Dis 85: 352-355. https://doi.org/10.1016/j.diagmicrobio.2016.03.019.
242. Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA. 2015. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother 59: 1680-1689. https://doi.org/10.1128/AAC.04808-14.
243. Neonakis IK, Spandidos DA, Petinaki E. 2011. Confronting multidrugresistant Acinetobacter baumannii: a review. Int J Antimicrob Agents 37: 102-109. https://doi.org/10.1016/j.ijantimicag.2010.10.014.
244. Vila J, Ruiz J, Goni P, Jimenez de Anta T. 1997. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 39: 757-762. https://doi.org/10.1093/ jac/39.6.757.
245. Hujer KM, Hujer AM, Endimiani A, Thomson JM, Adams MD, Goglin K, Rather PN, Pennella TT, Massire C, Eshoo MW, Sampath R, Blyn LB, Ecker DJ, Bonomo RA. 2009. Rapid determination of quinolone resistance in Acinetobacter spp. J Clin Microbiol 47: 1436-1442. https://doi.org/10.1128/JCM.02380-08.
246. Fishbain J, Peleg AY. 2010. Treatment of Acinetobacter infections. Clin Infect Dis 51: 79-84. https://doi.org/10.1086/653120.
247. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21: 538-582. https:// doi.org/10.1128/CMR.00058-07.
248. Rhomberg PR, Jones RN. 2009. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 65: 414-426. https://doi.org/10.1016/j.diagmicrobio.2009.08.020.
249. Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y. 2015. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 60: 1295-1303. https:// doi.org/10.1093/cid/civ048.
250. Choi IS, Lee YJ, Wi YM, Kwan BS, Jung KH, Hong WP, Kim JM. 2016. Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy. Int J Antimicrob Agents 48: 175-180. https://doi.org/10.1016/ j.ijantimicag.2016.05.011.
251. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. 2010. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138: 1333-1339. https://doi.org/10.1378/chest.10-0463.
252. Linden PK, Paterson DL. 2006. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 43(Suppl 2): S89-S94.
253. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. 2010. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 43: 323-331. https://doi.org/10.1016/S1684-1182(10)60050-3.
254. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. 2010. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 65: 2645-2649. https://doi.org/10.1093/jac/dkq360.
255. Lu Q, Luo R, Bodin L, Yang J, Zahr N, Aubry A, Golmard JL, Rouby JJ, Nebulized Antibiotics Study Group. 2012. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 117: 1335-1347. https://doi.org/10.1097/ ALN.0b013e31827515de.
256. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. 2005. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 41: 754-757. https://doi.org/10.1086/432583.
257. Kuo SC, Lee YT, Yang SP, Chen CP, Chen TL, Hsieh SL, Siu LK, Fung CP. 2012. Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study. Clin Microbiol Infect 18: 870-876. https://doi.org/10.1111/j.1469-0691.2011.03682.x.
258. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. 2010. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 16: 1230-1236. https://doi.org/10.1111/j.1469-0691.2009.03040.x.
259. Falagas ME, Siempos II, Rafailidis PI, Korbila IP, Ioannidou E, Michalopoulos A. 2009. Inhaled colistin as monotherapy for multidrug-resistant gram (-) nosocomial pneumonia: a case series. Respir Med 103: 707-713. https://doi.org/10.1016/j.rmed.2008.11.018.
260. Arnold HM, Sawyer AM, Kollef MH. 2012. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir Care 57: 1226-1233. https://doi.org/10.4187/respcare.01556.
261. Choi HK, Kim YK, Kim HY, Uh Y. 2014. Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii. Yonsei Med J 55: 118-125. https://doi.org/10.3349/ymj.2014.55.1.118.
262. Demirdal T, Sari US, Nemli SA. 2016. Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii? Ann Clin Microbiol Antimicrob 15: 11. https://doi.org/10.1186/s12941-016-0123-7.
263. Kang CH, Tsai CM, Wu TH, Wu HY, Chung MY, Chen CC, Huang YC, Liu SF, Liao DL, Niu CK, Lee CH, Yu HR. 2014. Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity. Pediatr Pulmonol 49: 381-388. https://doi.org/10.1002/ppul.22750.
264. Oikonomou O, Sarrou S, Papagiannitsis CC, Georgiadou S, Mantzarlis K, Zakynthinos E, Dalekos GN, Petinaki E. 2015. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: mechanisms of resistance, molecular identification and epidemiological data. BMC Infect Dis 15: 559. https://doi.org/10.1186/s12879-015-1297-x.
265. Pogue JM, Cohen DA, Marchaim D. 2015. Polymyxin-resistant Acinetobacter baumannii: urgent action needed. Clin Infect Dis 60: 1304-1307. https://doi.org/10.1093/cid/civ044.
266. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67: 1607-1615. https://doi.org/10.1093/jac/dks084.
267. Craig WA, Salamone FR. 1988. Do antibiotic combinations prevent the emergence of resistant organisms? Infect Control Hosp Epidemiol 9: 417-419. https://doi.org/10.2307/30144309.
268. Tamma PD, Cosgrove SE, Maragakis LL. 2012. Combination therapy for treatment of infections with Gram-negative bacteria. Clin Microbiol Rev 25: 450-470. https://doi.org/10.1128/CMR.05041-11.
269. Fischbach MA. 2011. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 14: 519-523. https://doi.org/10.1016/j.mib.2011.08.003.
270. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. 2005. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 41: 149-158. https://doi.org/10.1086/430912.
271. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. 2014. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014: CD003344. https://doi.org/10.1002/14651858.CD003344.pub3.
272. Poulikakos P, Tansarli GS, Falagas ME. 2014. Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis 33: 1675-1685. https:// doi.org/10.1007/s10096-014-2124-9.
273. Tuon FF, Rocha JL, Merlini AB. 2015. Combined therapy for multi-drugresistant Acinetobacter baumannii infection-is there evidence outside the laboratory? J Med Microbiol 64: 951-959. https://doi.org/10.1099/ jmm.0.000144.
274. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R. 2013. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57: 349-358. https://doi.org/10.1093/cid/cit253.
275. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. 2013. In vitro synergy of polymyxins and carbapenems: systematic review and meta analysis. Antimicrob Agents Chemother 57: 5104-5111. https://doi.org/10.1128/AAC.01230-13.
276. Oleksiuk LM, Nguyen MH, Press EG, Updike CL, O’Hara JA, Doi Y, Clancy CJ, Shields RK. 2014. In vitro responses of Acinetobacter baumannii to two-and three-drug combinations following exposure to colistin and doripenem. Antimicrob Agents Chemother 58: 1195-1199. https:// doi.org/10.1128/AAC.01779-13.
277. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F, Aslan T, Bekiroglu N, Cesur S, Celik AD, Dogan M, Durdu B, Duygu F, Engin A, Engin DO, Gonen I, Guclu E, Guven T, Hatipoglu CA, Hosoglu S, Karahocagil MK, Kilic AU, Ormen B, Ozdemir D, Ozer S, Oztoprak N, Sezak N, Turhan V, Turker N, Yilmaz H. 2014. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drugresistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 33: 1311-1322. https://doi.org/10.1007/s10096-014-2070-6.
278. Dinc G, Demiraslan H, Elmali F, Ahmed SS, Alp E, Doganay M. 2015. Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii. New Microbiol 38: 67-73.
279. Le Minh V, Thi Khanh Nhu N, Vinh Phat V, Thompson C, Huong Lan NP, Thieu Nga TV, Thanh Tam PT, Tuyen HT, Hoang Nhu TD, Van Hao N, Thi Loan H, Minh Yen L, Parry CM, Trung Nghia HD, Campbell JI, Hien TT, Thwaites L, Thwaites G, Van Vinh Chau N, Baker S. 2015. In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilatorassociated pneumonia in Vietnam. J Med Microbiol 64: 1162-1169. https://doi.org/10.1099/jmm.0.000137.
280. Claeys KC, Fiorvento AD, Rybak MJ. 2014. A review of novel combinations of colistin and lipopeptide or glycopeptide antibiotics for the treatment of multidrug-resistant Acinetobacter baumannii. Infect Dis Ther 3: 69-81. https://doi.org/10.1007/s40121-014-0051-9.
281. Garnacho-Montero J, Amaya-Villar R, Gutierrez-Pizarraya A, Espejo-Gutierrez de Tena E, Artero-Gonzalez ML, Corcia-Palomo Y, Bautista-Paloma J. 2013. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy 59: 225-231. https://doi.org/10.1159/000356004.
282. Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, Inkaya AC, De Pascale G, Grilli E, Tumbarello M, Akova M. 2014. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother 58: 851-858. https://doi.org/10.1128/AAC.00871-13.
283. Entasis herapeutics. 2016. Entasis Therapeutics: Pipeline. Entasis Therapeutics, Waltham, MA.
284. Spero Therapeutics. 2016. Spero Therapeutics unveils data on lead potentiator candidate for the treatment of multidrug resistant Gramnegative infections at ASM Microbe 2016. Spero Therapeutics, Cambridge, MA.
285. Flamm RK, Rhomberg PR, Jones RN, Farrell DJ. 2015. In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Antimicrob Agents Chemother 59: 2280-2285. https://doi.org/10.1128/AAC.04840-14.
286. Tetraphase Pharmaceuticals. 2016. Tetraphase Pharmaceuticals provides update on eravacycline regulatory and development status. Tetraphase Pharmaceuticals, Watertown, MA.
287. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Olafsdottir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH. 2016. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 16: 239-251. https://doi.org/10.1016/S1473-3099(15)00466-1.
288. Garcia-Quintanilla M, Pulido MR, Lopez-Rojas R, Pachon J, McConnell MJ. 2013. Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol 21: 157-163. https://doi.org/10.1016/ j.tim.2012.12.002.
289. Eaton MD. 1934. Studies on Pneumococcus variation: I. Variants characterized by rapid lysis and absence of normal growth under the routine method of cultivation. J Bacteriol 27: 271-291.
290. National Institute of Allergy and Infectious Diseases. 2016. Bacteriophage therapy: an alternative strategy to combat drug resistance. 20 to 21 July 2015. National Institute of Allergy and Infectious Diseases, Rockville, MD.
291. Defraine V, Schuermans J, Grymonprez B, Govers SK, Aertsen A, Fauvart M, Michiels J, Lavigne R, Briers Y. 2016. Efficacy of artilysin Art-175 against resistant and persistent Acinetobacter baumannii. Antimicrob Agents Chemother 60: 3480-3488. https://doi.org/10.1128/AAC.00285-16.
292. Jeon J, Ryu CM, Lee JY, Park JH, Yong D, Lee K. 2016. In vivo application of bacteriophage as a potential therapeutic agent to control OXA-66-like carbapenemase-producing Acinetobacter baumannii strains belonging to sequence type 357. Appl Environ Microbiol 82: 4200-4208. https://doi.org/10.1128/AEM.00526-16.
293. Wang Y, Mi Z, Niu W, An X, Yuan X, Liu H, Li P, Liu Y, Feng Y, Huang Y, Zhang X, Zhang Z, Fan H, Peng F, Tong Y, Bai C. 2016. Intranasal treatment with bacteriophage rescues mice from Acinetobacter baumannii-mediated pneumonia. Future Microbiol 11: 631-641. https://doi.org/10.2217/fmb.16.11.
294. Shivaswamy VC, Kalasuramath SB, Sadanand CK, Basavaraju AK, Ginnavaram V, Bille S, Ukken SS, Pushparaj UN. 2015. Ability of bacteriophage in resolving wound infection caused by multidrug-resistant Acinetobacter baumannii in uncontrolled diabetic rats. Microb Drug Resist 21: 171-177. https://doi.org/10.1089/mdr.2014.0120.
295. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA. 2015. Novel phage lysin capable of killing the multidrug-resistant Gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 59: 1983-1991. https://doi.org/10.1128/AAC.04641-14.
296. Thandar M, Lood R, Winer BY, Deutsch DR, Euler CW, Fischetti VA. 2016. Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 60: 2671-2679. https://doi.org/10.1128/AAC.02972-15.
297. Kitti T, Thummeepak R, Leungtongkam U, Kunthalert D, Sitthisak S. 2015. Efficacy of Acinetobacter baumannii bacteriophage cocktail on Acinetobacter baumannii growth. Afr J Microbiol Res 9: 2159-2165.
298. Regeimbal JM, Jacobs AC, Corey BW, Henry MS, Thompson MG, Pavlicek RL, Quinones J, Hannah RM, Ghebremedhin M, Crane NJ, Zurawski DV, Teneza-Mora NC, Biswas B, Hall ER. 2016. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob Agents Chemother 60: 5806-5816. https://doi.org/10.1128/AAC.02877-15.
299. Perez F, Bonomo RA. 2014. Vaccines for Acinetobacter baumannii: thinking "out of the box". Vaccine 32: 2537-2539. https://doi.org/10.1016/j.vaccine.2014.03.031.
300. Lin L, Tan B, Pantapalangkoor P, Ho T, Hujer AM, Taracila MA, Bonomo RA, Spellberg B. 2013. Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine 31: 313-318. https://doi.org/10.1016/j.vaccine.2012.11.008.
301. Garg N, Singh R, Shukla G, Capalash N, Sharma P. 2016. Immunoprotective potential of in silico predicted Acinetobacter baumannii outer membrane nuclease, NucAb. Int J Med Microbiol 306: 1-9. https:// doi.org/10.1016/j.ijmm.2015.10.005.
302. Badmasti F, Ajdary S, Bouzari S, Fooladi AA, Shahcheraghi F, Siadat SD. 2015. Immunological evaluation of OMV(PagL)+Bap(1-487aa) and AbOmpA(8-346aa)_Bap(1-487aa) as vaccine candidates against Acinetobacter baumannii sepsis infection. Mol Immunol 67(2 Part B): 552-558. https://doi.org/10.1016/j.molimm.2015.07.031.
303. Huang W, Wang S, Yao Y, Xia Y, Yang X, Long Q, Sun W, Liu C, Li Y, Ma Y. 2015. OmpW is a potential target for eliciting protective immunity against Acinetobacter baumannii infections. Vaccine 33: 4479-4485. https://doi.org/10.1016/j.vaccine.2015.07.031.
304. Garcia-Quintanilla M, Pulido MR, Pachon J, McConnell MJ. 2014. Immunization with lipopolysaccharide-deficient whole cells provides protective immunity in an experimental mouse model of Acinetobacter baumannii infection. PLoS One 9: e114410. https://doi.org/10.1371/ journal.pone.0114410.
305. Skaar EP. 2010. The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog 6: e1000949. https://doi.org/10.1371/journal.ppat.1000949.
306. Bruhn KW, Spellberg B. 2015. Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections. Curr Opin Microbiol 27: 57-61. https://doi.org/10.1016/j.mib.2015.07.005.
307. Kehl-Fie TE, Skaar EP. 2010. Nutritional immunity beyond iron: a role for manganese and zinc. Curr Opin Chem Biol 14: 218-224. https://doi.org/10.1016/j.cbpa.2009.11.008.
308. Mortensen BL, Skaar EP. 2013. The contribution of nutrient metal acquisition and metabolism to Acinetobacter baumannii survival within the host. Front Cell Infect Microbiol 3: 95. https://doi.org/10.3389/fcimb.2013.00095.
309. Zimbler DL, Penwell WF, Gaddy JA, Menke SM, Tomaras AP, Connerly PL, Actis LA. 2009. Iron acquisition functions expressed by the human pathogen Acinetobacter baumannii. Biometals 22: 23-32. https:// doi.org/10.1007/s10534-008-9202-3.
310. Nudel C, Gonzalez R, Castaneda N, Mahler G, Actis LA. 2001. Influence of iron on growth, production of siderophore compounds, membrane proteins, and lipase activity in Acinetobacter calcoaceticus BD 413. Microbiol Res 155: 263-269. https://doi.org/10.1016/S0944-5013(01)80003-3.
311. Penwell WF, Arivett BA, Actis LA. 2012. The Acinetobacter baumannii entA gene located outside the acinetobactin cluster is critical for siderophore production, iron acquisition and virulence. PLoS One 7: e36493. https://doi.org/10.1371/journal.pone.0036493.
312. Zimbler DL, Park TM, Arivett BA, Penwell WF, Greer SM, Woodruff TM, Tierney DL, Actis LA. 2012. Stress response and virulence functions of the Acinetobacter baumannii NfuA Fe-S scaffold protein. J Bacteriol 194: 2884-2893. https://doi.org/10.1128/JB.00213-12.
313. de Leseleuc L, Harris G, KuoLee R, Xu HH, Chen W. 2014. Serum resistance, gallium nitrate tolerance and extrapulmonary dissemination are linked to heme consumption in a bacteremic strain of Acinetobacter baumannii. Int J Med Microbiol 304: 360-369. https://doi.org/10.1016/j.ijmm.2013.12.002.
314. Dorsey CW, Tomaras AP, Connerly PL, Tolmasky ME, Crosa JH, Actis LA. 2004. The siderophore-mediated iron acquisition systems of Acinetobacter baumannii ATCC 19606 and Vibrio anguillarum 775 are structurally and functionally related. Microbiology 150: 3657-3667. https:// doi.org/10.1099/mic.0.27371-0.
315. Fiester SE, Nwugo CC, Penwell WF, Neary JM, Beckett AC, Arivett BA, Schmidt RE, Geiger SC, Connerly PL, Menke SM, Tomaras AP, Actis LA. 2015. Role of the carboxy terminus of SecA in iron acquisition, protein translocation, and virulence of the bacterial pathogen Acinetobacter baumannii. Infect Immun 83: 1354-1365. https://doi.org/10.1128/ IAI.02925-14.
316. Gaddy JA, Arivett BA, McConnell MJ, Lopez-Rojas R, Pachon J, Actis LA. 2012. Role of acinetobactin-mediated iron acquisition functions in the interaction of Acinetobacter baumannii strain ATCC 19606T with human lung epithelial cells, Galleria mellonella caterpillars, and mice. Infect Immun 80: 1015-1024. https://doi.org/10.1128/IAI.06279-11.
317. Hood MI, Mortensen BL, Moore JL, Zhang Y, Kehl-Fie TE, Sugitani N, Chazin WJ, Caprioli RM, Skaar EP. 2012. Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration. PLoS Pathog 8: e1003068. https://doi.org/10.1371/journal.ppat.1003068.
318. Thompson MG, Corey BW, Si Y, Craft DW, Zurawski DV. 2012. Antibacterial activities of iron chelators against common nosocomial pathogens. Antimicrob Agents Chemother 56: 5419-5421. https://doi.org/10.1128/AAC.01197-12.
319. Mortensen BL, Rathi S, Chazin WJ, Skaar EP. 2014. Acinetobacter baumannii response to host-mediated zinc limitation requires the transcriptional regulator Zur. J Bacteriol 196: 2616-2626. https://doi.org/10.1128/JB.01650-14.
320. Nairn BL, Lonergan ZR, Wang J, Braymer JJ, Zhang Y, Calcutt MW, Lisher JP, Gilston BA, Chazin WJ, de Crecy-Lagard V, Giedroc DP, Skaar EP. 2016. The response of Acinetobacter baumannii to zinc starvation. Cell Host Microbe 19: 826-836. https://doi.org/10.1016/j.chom.2016.05.007.
321. Choi CH, Hyun SH, Lee JY, Lee JS, Lee YS, Kim SA, Chae JP, Yoo SM, Lee JC. 2008. Acinetobacter baumannii outer membrane protein A targets the nucleus and induces cytotoxicity. Cell Microbiol 10: 309-319.
322. Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin JH, Kim JM, Lee YC, Seol SY, Cho DT, Lee JC. 2009. Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins. FEMS Microbiol Lett 301: 224-231. https://doi.org/10.1111/ j.1574-6968.2009.01820.x.
323. Kim SW, Oh MH, Jun SH, Jeon H, Kim SI, Kim K, Lee YC, Lee JC. 2016. Outer membrane protein A plays a role in pathogenesis of Acinetobacter nosocomialis. Virulence 7: 413-426. https://doi.org/10.1080/21505594.2016.1140298.
324. Tilley D, Law R, Warren S, Samis JA, Kumar A. 2014. CpaA a novel protease from Acinetobacter baumannii clinical isolates deregulates blood coagulation. FEMS Microbiol Lett 356: 53-61. https://doi.org/10.1111/1574-6968.12496.
325. Liou ML, Soo PC, Ling SR, Kuo HY, Tang CY, Chang KC. 2014. The sensor kinase BfmS mediates virulence in Acinetobacter baumannii. J Microbiol Immunol Infect 47: 275-281. https://doi.org/10.1016/ j.jmii.2012.12.004.
326. Fernandez-Cuenca F, Smani Y, Gomez-Sanchez MC, Docobo-Perez F, Caballero-Moyano FJ, Dominguez-Herrera J, Pascual A, Pachon J. 2011. Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like. Int J Antimicrob Agents 38: 548-549. https://doi.org/10.1016/j.ijantimicag.2011.08.002.
327. Bahl CD, Hvorecny KL, Bridges AA, Ballok AE, Bomberger JM, Cady KC, O’Toole GA, Madden DR. 2014. Signature motifs identify an Acinetobacter Cif virulence factor with epoxide hydrolase activity. J Biol Chem 289: 7460-7469. https://doi.org/10.1074/jbc.M113.518092.
328. Alvarez-Fraga L, Perez A, Rumbo-Feal S, Merino M, Vallejo JA, Ohneck EJ, Edelmann RE, Beceiro A, Vazquez-Ucha JC, Valle J, Actis LA, Bou G, Poza M. 2016. Analysis of the role of the LH92_11085 gene of a biofilm hyper-producing Acinetobacter baumannii strain on biofilm formation and attachment to eukaryotic cells. Virulence 7: 443-455. https:// doi.org/10.1080/21505594.2016.1145335.
329. Sun D, Crowell SA, Harding CM, De Silva PM, Harrison A, Fernando DM, Mason KM, Santana E, Loewen PC, Kumar A, Liu Y. 2016. KatG and KatE confer Acinetobacter resistance to hydrogen peroxide but sensitize bacteria to killing by phagocytic respiratory burst. Life Sci 148: 31-40. https://doi.org/10.1016/j.lfs.2016.02.015.
330. Heindorf M, Kadari M, Heider C, Skiebe E, Wilharm G. 2014. Impact of Acinetobacter baumannii superoxide dismutase on motility, virulence, oxidative stress resistance and susceptibility to antibiotics. PLoS One 9: e101033. https://doi.org/10.1371/journal.pone.0101033.
331. Esterly JS, McLaughlin MM, Malczynski M, Qi C, Zembower TR, Scheetz MH. 2014. Pathogenicity of clinical Acinetobacter baumannii isolates in a Galleria mellonella host model according to bla(OXA-40) gene and epidemiological outbreak status. Antimicrob Agents Chemother 58: 1240-1242. https://doi.org/10.1128/AAC.02201-13.
332. Srinivasan VB, Vaidyanathan V, Rajamohan G. 2015. AbuO, a TolC-like outer membrane protein of Acinetobacter baumannii, is involved in antimicrobial and oxidative stress resistance. Antimicrob Agents Chemother 59: 1236-1245. https://doi.org/10.1128/AAC.03626-14.
333. Durante-Mangoni E, Del Franco M, Andini R, Bernardo M, Giannouli M, Zarrilli R. 2015. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 82: 222-226. https://doi.org/10.1016/ j.diagmicrobio.2015.03.013.
334. Wand ME, Bock LJ, Bonney LC, Sutton JM. 2015. Retention of virulence following adaptation to colistin in Acinetobacter baumannii reflects the mechanism of resistance. J Antimicrob Chemother 70: 2209-2216. https://doi.org/10.1093/jac/dkv097.
335. Stahl J, Bergmann H, Gottig S, Ebersberger I, Averhoff B. 2015. Acinetobacter baumannii virulence is mediated by the concerted action of three phospholipases D. PLoS One 10: e0138360. https://doi.org/10.1371/journal.pone.0138360.
336. Repizo GD, Gagne S, Foucault-Grunenwald ML, Borges V, Charpentier X, Limansky AS, Gomes JP, Viale AM, Salcedo SP. 2015. Differential role of the T6SS in Acinetobacter baumannii virulence. PLoS One 10: e0138265. https://doi.org/10.1371/journal.pone.0138265.
337. Vila-Farres X, Ferrer-Navarro M, Callarisa AE, Marti S, Espinal P, Gupta S, Rolain JM, Giralt E, Vila J. 2015. Loss of LPS is involved in the virulence and resistance to colistin of colistin-resistant Acinetobacter nosocomialis mutants selected in vitro. J Antimicrob Chemother 70: 2981-2986. https://doi.org/10.1093/jac/dkv244.
338. Liu D, Liu ZS, Hu P, Cai L, Fu BQ, Li YS, Lu SY, Liu NN, Ma XL, Chi D, Chang J, Shui YM, Li ZH, Ahmad W, Zhou Y, Ren HL. 2016. Characterization of surface antigen protein 1 (SurA1) from Acinetobacter baumannii and its role in virulence and fitness. Vet Microbiol 186: 126-138. https://doi.org/10.1016/j.vetmic.2016.02.018.
339. Nho JS, Jun SH, Oh MH, Park TI, Choi CW, Kim SI, Choi CH, Lee JC. 2015. Acinetobacter nosocomialis secretes outer membrane vesicles that induce epithelial cell death and host inflammatory responses. Microb Pathog 81: 39-45. https://doi.org/10.1016/j.micpath.2015.03.012.
340. Johnson TL, Waack U, Smith S, Mobley H, Sandkvist M. 2015. Acinetobacter baumannii is dependent on the type II secretion system and its substrate LipA for lipid utilization and in vivo fitness. J Bacteriol 198: 711-719. https://doi.org/10.1128/JB.00622-15.
341. Harding CM, Kinsella RL, Palmer LD, Skaar EP, Feldman MF. 2016. Medically relevant Acinetobacter species require a type II secretion system and specific membrane-associated chaperones for the export of multiple substrates and full virulence. PLoS Pathog 12: e1005391. https://doi.org/10.1371/journal.ppat.1005391.
342. Lopez-Rojas R, McConnell MJ, Jimenez-Mejias ME, Dominguez-Herrera J, Fernandez-Cuenca F, Pachon J. 2013. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob Agents Chemother 57: 4587-4589. https://doi.org/10.1128/AAC.00543-13.
343. Hraiech S, Roch A, Lepidi H, Atieh T, Audoly G, Rolain JM, Raoult D, Brunel JM, Papazian L, Bregeon F. 2013. Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother 57: 5120-5121. https://doi.org/10.1128/AAC.00700-13.
344. Smani Y, Lopez-Rojas R, Dominguez-Herrera J, Docobo-Perez F, Marti S, Vila J, Pachon J. 2012. In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii. Clin Microbiol Infect 18: E1-E4. https://doi.org/10.1111/j.1469-0691.2011.03695.x.
345. Iwashkiw JA, Seper A, Weber BS, Scott NE, Vinogradov E, Stratilo C, Reiz B, Cordwell SJ, Whittal R, Schild S, Feldman MF. 2012. Identification of a general O-linked protein glycosylation system in Acinetobacter baumannii and its role in virulence and biofilm formation. PLoS Pathog 8: e1002758. https://doi.org/10.1371/journal.ppat.1002758.
346. Rumbo C, Tomas M, Fernandez Moreira E, Soares NC, Carvajal M, Santillana E, Beceiro A, Romero A, Bou G. 2014. The Acinetobacter baumannii Omp33-36 porin is a virulence factor that induces apoptosis and modulates autophagy in human cells. Infect Immun 82: 4666-4680. https://doi.org/10.1128/IAI.02034-14.
347. Cerqueira GM, Kostoulias X, Khoo C, Aibinu I, Qu Y, Traven A, Peleg AY. 2014. A global virulence regulator in Acinetobacter baumannii and its control of the phenylacetic acid catabolic pathway. J Infect Dis 210: 46-55. https://doi.org/10.1093/infdis/jiu024.
348. Elhosseiny NM, Amin MA, Yassin AS, Attia AS. 2015. Acinetobacter baumannii universal stress protein A plays a pivotal role in stress response and is essential for pneumonia and sepsis pathogenesis. Int J Med Microbiol 305: 114-123. https://doi.org/10.1016/j.ijmm.2014.11.008.